Division of Genetics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Department of Genetics, School of Medicine, Stanford University, Stanford, CA, USA.
Nat Med. 2024 Feb;30(2):360-372. doi: 10.1038/s41591-023-02784-9. Epub 2024 Feb 14.
The search for biomarkers that quantify biological aging (particularly 'omic'-based biomarkers) has intensified in recent years. Such biomarkers could predict aging-related outcomes and could serve as surrogate endpoints for the evaluation of interventions promoting healthy aging and longevity. However, no consensus exists on how biomarkers of aging should be validated before their translation to the clinic. Here, we review current efforts to evaluate the predictive validity of omic biomarkers of aging in population studies, discuss challenges in comparability and generalizability and provide recommendations to facilitate future validation of biomarkers of aging. Finally, we discuss how systematic validation can accelerate clinical translation of biomarkers of aging and their use in gerotherapeutic clinical trials.
近年来,人们对能够量化生物衰老的生物标志物(尤其是基于“组学”的生物标志物)的研究日益深入。这些生物标志物可以预测与衰老相关的结果,并且可以作为评估促进健康衰老和长寿的干预措施的替代终点。然而,在将衰老生物标志物转化到临床应用之前,如何对其进行验证尚未达成共识。在这里,我们综述了当前在人群研究中评估衰老组学生物标志物预测价值的努力,讨论了可比性和普遍性方面的挑战,并提出了建议,以促进衰老生物标志物的未来验证。最后,我们讨论了系统验证如何加速衰老生物标志物的临床转化及其在老年治疗临床试验中的应用。